Skip to main content
Clinical Trials/NCT01834339
NCT01834339
Terminated
Phase 2

A Randomized, Parallel-Group (Autogenous EVPOME Versus AlloDerm Without Incorporation of Keratinocytes) Study in Subjects Reconstructed With Large Defect Mandibular Resection in Need of Vestibuloplasty for Dental Rehabilitation

Stephen E. Feinberg1 site in 1 country1 target enrollmentSeptember 2013

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Mandibular Injuries
Sponsor
Stephen E. Feinberg
Enrollment
1
Locations
1
Primary Endpoint
Percent Graft Contracture
Status
Terminated
Last Updated
8 years ago

Overview

Brief Summary

The purpose of this study is to compare the safety and effectiveness of performing oral reconstructive surgeries using either AlloDerm, a product commonly used for this purpose, or AlloDerm that has been overlaid with the subject's oral mucosal cells and developed into a type of graft that is called an ex vivo produced oral mucosal equivalent, EVPOME.

Registry
clinicaltrials.gov
Start Date
September 2013
End Date
December 2015
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Stephen E. Feinberg
Responsible Party
Sponsor Investigator
Principal Investigator

Stephen E. Feinberg

Professor & Associate Chair of Research

University of Michigan

Eligibility Criteria

Inclusion Criteria

  • Be an adult over 18 years of age
  • Have a free fibular graft placed more than six months ago that has been used for restoration of mandibular continuity.
  • Be in need of surgery to increase the vestibular fold of the grafted mandible for placement of a dental prosthesis to restore function

Exclusion Criteria

  • Any liver, kidney, heart, blood, metabolic or systemic disease which may make execution of the protocol of interpretation of the results difficult
  • A history of syphilis, HIV, Hepatitis B or Hepatitis C
  • Pregnancy or planning to become pregnant
  • Known or suspected allergy to bovine (cow) protein
  • Receiving radiation
  • Currently smoking or using tobacco products
  • Talking medication that can result in gingival enlargement (Cyclosporine, Dilantin, calcium channel blockers)
  • Allergy to any of the following antibiotics Gentamycin, Cefoxitin, Lincomycin, Polymyxin B, Vancomycin, cephalosporins, or clindamycin
  • Allergy to Polysorbate 20

Outcomes

Primary Outcomes

Percent Graft Contracture

Time Frame: 2-24 weeks

During surgery, after preparation of the recipient bed, the recipient bed and the graft will be measured for the maximum distance between non-resorbable sutures placed at the margins of the graft. Post-surgical measurements of the graft site will be taken at visits 5, 6, 7, and 8 and compared to original graft size to assess percentage of graft contracture.

Secondary Outcomes

  • Degree of Epithelialized Tissue(4 weeks after surgery)
  • Laser Doppler Flowmetry (LDF)(Visit 1 and 2 and 4 weeks after surgery)

Study Sites (1)

Loading locations...

Similar Trials